Brief: Revolution Medicines Reports U.S. FDA Approves Its RASONQUE
26/08/2026 18:39
BRIEF-Revolution Medicines Reports U.S. FDA Approves Its RASONQUE Aug 26 (Reuters) - Revolution Medicines, Inc. RVMD.O:
U.S. FDA APPROVES REVOLUTION MEDICINES’ RASONQUE™ (DARAXONRASIB), THE FIRST BROAD RAS-TARGETED MEDICINE IN METASTATIC PANCREATIC CANCER
REVOLUTION MEDICINES, - RASONQUE 300 MG ONCE-DAILY ORAL TABLETS NOW AVAILABLE IN THE U.S.
Source text: ID:nGNX4H3Fzw
Further company coverage: RVMD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Revolution Medicines
See all newsAnalysis: Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug
Brief: CHMP Recommends Granting Marketing Authorisation For Rasonque For Metastatic Pancreatic Cancer In EU
Revolution Medicines wins EU committee backing for pancreatic cancer treatment (updated)
EMA recommends approval of Revolution's pancreatic cancer drug
Revolution Medicines falls on pancreatic cancer drug data concerns